Bb Biotech Ag Stock Current Ratio
| BION Stock | CHF 37.30 0.15 0.40% |
BB Biotech AG fundamentals help investors to digest information that contributes to BB Biotech's financial success or failures. It also enables traders to predict the movement of BION Stock. The fundamental analysis module provides a way to measure BB Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BB Biotech stock.
BION |
BB Biotech AG Company Current Ratio Analysis
BB Biotech's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current BB Biotech Current Ratio | 9.72 X |
Most of BB Biotech's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BB Biotech AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, BB Biotech AG has a Current Ratio of 9.72 times. This is 234.02% higher than that of the Healthcare sector and 38.86% higher than that of the Biotechnology industry. The current ratio for all Switzerland stocks is notably lower than that of the firm.
BION Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BB Biotech's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BB Biotech could also be used in its relative valuation, which is a method of valuing BB Biotech by comparing valuation metrics of similar companies.BB Biotech is currently under evaluation in current ratio category among its peers.
BION Fundamentals
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0411 | |||
| Operating Margin | 1.25 % | |||
| Current Valuation | 509.23 M | |||
| Shares Outstanding | 54.99 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 7.82 % | |||
| Price To Earning | 23.12 X | |||
| Price To Book | 1.28 X | |||
| Price To Sales | 814,184 X | |||
| Revenue | (396.22 M) | |||
| Gross Profit | 4 K | |||
| EBITDA | (403.75 M) | |||
| Net Income | (404.81 M) | |||
| Cash And Equivalents | 2.83 M | |||
| Cash Per Share | 65.76 X | |||
| Debt To Equity | 11.30 % | |||
| Current Ratio | 9.72 X | |||
| Book Value Per Share | 49.62 X | |||
| Cash Flow From Operations | (94.79 M) | |||
| Earnings Per Share | (16.73) X | |||
| Target Price | 69.52 | |||
| Number Of Employees | 10 | |||
| Beta | 0.87 | |||
| Market Capitalization | 3.15 B | |||
| Total Asset | 3.64 B | |||
| Annual Yield | 0.05 % | |||
| Five Year Return | 4.63 % | |||
| Net Asset | 3.64 B | |||
| Last Dividend Paid | 3.85 |
About BB Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BB Biotech AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BB Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BB Biotech AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BION Stock Analysis
When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.